Developer docs
API playgroundTry for free, no card

Search company profiles

Abivax

Full company profile

uuid00004fx

Namestring
Abivax
Legal namestring
Abivax SA
Websiteurl
abivax.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Abivax SA is a clinical-stage biotechnology company headquartered in Paris, France, with dual listings on Euronext Paris and Nasdaq (ticker ABVX). Founded in 2013, the company is developing obefazimod (ABX464), an investigational oral once-daily small molecule that is the first and only clinical-stage enhancer of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Under dysregulated inflammatory conditions, enhanced miR-124 expression stabilizes multiple cytokines and chemokines toward homeostatic levels, addressing multiple pathways simultaneously to potentially reduce compensatory immune escape. Obefazimod is in Phase 3 development for moderately to severely active ulcerative colitis (positive ABTECT induction and maintenance data, with NDA submission targeted for Q4 2026) and Phase 2b for Crohn's disease (ENHANCE-CD, data anticipated mid-2027). Preclinical evidence also indicates dual anti-inflammatory and anti-fibrotic activity.

Abivax has no commercial revenue and operates at a loss, with FY2025 R&D expenses of €177.8 million and net loss of €336.1 million. The cash position of €530.4 million at year-end 2025 has been augmented by a $920 million public offering in July 2026, extending runway into Q2 2029. The company is investing heavily in US commercialization infrastructure, including a Waltham, Massachusetts headquarters and a senior leadership team recruited from Takeda (Entyvio), AstraZeneca-target CinCor, Landos Biopharma, and Roche/Genentech, with a first US launch targeted for 2027. Beyond obefazimod, Abivax holds a proprietary chemical library supporting follow-on compound research in inflammation.

Short descriptiontext

Abivax is a clinical-stage biotechnology company developing obefazimod, a first-in-class oral miR-124 enhancer, for ulcerative colitis and Crohn's disease, with NDA submission planned for Q4 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inflammatory bowel disease, clinical-stage biotechnology, small molecule therapeutics, microRNA therapeutics, ulcerative colitis treatment
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Inflammatory Bowel Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1No Current Revenue
TypeSubscription Recurring
Description

Abivax is a clinical-stage biotechnology company with no approved products or commercial revenue. The company reported a net loss of €48.5 million in Q1 2026 and a full-year 2025 net loss of €336.1 million. R&D expenses were €49.5 million in Q1 2026 and €177.8 million for full-year 2025.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Abivax is developing obefazimod (ABX464), an investigational oral once-daily small molecule and the first clinical-stage enhancer of microRNA-124 (miR-124) expression in immune cells, designed to stabilize the dysregulated inflammatory response in chronic inflammatory diseases. The lead indication is moderately-to-severely active ulcerative colitis (Phase 3 ABTECT program) with Phase 2b development in Crohn's disease (ENHANCE-CD), supported by a proprietary chemical library of follow-on candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Clinical remission rate of 50.8% (25mg) and 51.3% (50mg) versus 10.4% placebo at Week 44 in Phase 3 ABTECT maintenance trial
+5 more records
Product overview1 text field

Abivax is a clinical-stage biotechnology company developing obefazimod, an oral small molecule therapeutic that enhances microRNA-124 (miR-124) expression to stabilize the immune response. The company's lead product candidate, obefazimod (ABX464), is in Phase 3 development for ulcerative colitis and Phase 2b for Crohn's disease. Abivax is also evaluating obefazimod in combination therapy for UC and exploring other inflammatory indications through follow-on compound research based on the same mechanistic concept.

Product and service1 record
1Obefazimod (ABX464)
CategoryInflammatory Bowel Disease Therapeutics
Description

Obefazimod is an investigational, orally administered once-daily small molecule therapeutic and the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. It is being developed for chronic inflammatory diseases, with lead indication in moderately to severely active ulcerative colitis (Phase 3 ABTECT) and Phase 2b development in Crohn's disease (ENHANCE-CD).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeOthersAnnounced on2026-02-21
Description

Medical congress where Abivax presented 22 abstracts at ECCO 2026 Annual Congress including first evidence of anti-fibrotic activity and new clinical efficacy and safety analyses for obefazimod.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-09-02
Description

Dechert advised Abivax on a €49.2 million financing that funded Phase 3 trials of obefazimod for ulcerative colitis.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Pfizer markets Velsipity (etrasimod), an oral S1P modulator approved for ulcerative colitis, making it a directly comparable oral UC competitor launched into the same gastroenterology prescriber base.

2Bristol Myers Squibb
TypeDirect peer
Description

BMS commercializes Zeposia (ozanimod), another oral UC therapy, positioning it as a directly comparable oral competitor with overlapping physician call points and payer access dynamics.

TypeBroad incumbent
Description

Lilly markets Omvoh (mirikizumab) for ulcerative colitis and Crohn's disease, making it a directly comparable IBD biologic competitor with established gastroenterology commercial infrastructure.

TypeBroad incumbent
Description

AbbVie dominates the IBD market with Skyrizi and Rinvoq, alongside its legacy Humira franchise; it is the leading incumbent that Abivax's oral obefazimod would need to compete against for share of voice and payer access.

TypeBroad incumbent
Description

J&J markets Stelara and Tremfya in IBD, two of the largest-selling UC and Crohn's therapies; it is a broad incumbent whose immunology franchise shapes the standard of care Abivax must displace.

TypeBroad incumbent
Description

Takeda markets Entyvio (vedolizumab), a ~$4.7B IBD biologic, and is the company Abivax hired its incoming CCO from — a directly comparable UC franchise and benchmark for Abivax's commercial ramp.

TypeEmerging player
Description

Landos is a smaller IBD-focused biotech (now part of AbbVie) whose leadership overlaps with Abivax's CMO, making it a thematic emerging peer in ulcerative colitis pipeline development.

TypeOthers
Description

Alnylam is a leader in RNA-based therapeutics and shares a mechanistic adjacency with Abivax, whose entire MOA is built around enhancing the microRNA miR-124 — making it thematically relevant as an RNA-platform comparator.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abivax

Inflammatory Bowel Disease Therapeuticsabivax.com

Abivax is a clinical-stage biotechnology company developing obefazimod, a first-in-class oral miR-124 enhancer, for ulcerative colitis and Crohn's disease, with NDA submission planned for Q4 2026.

What Abivax does

Abivax SA is a clinical-stage biotechnology company headquartered in Paris, France, with dual listings on Euronext Paris and Nasdaq (ticker ABVX). Founded in 2013, the company is developing obefazimod (ABX464), an investigational oral once-daily small molecule that is the first and only clinical-stage enhancer of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Under dysregulated inflammatory conditions, enhanced miR-124 expression stabilizes multiple cytokines and chemokines toward homeostatic levels, addressing multiple pathways simultaneously to potentially reduce compensatory immune escape. Obefazimod is in Phase 3 development for moderately to severely active ulcerative colitis (positive ABTECT induction and maintenance data, with NDA submission targeted for Q4 2026) and Phase 2b for Crohn's disease (ENHANCE-CD, data anticipated mid-2027). Preclinical evidence also indicates dual anti-inflammatory and anti-fibrotic activity.

Abivax has no commercial revenue and operates at a loss, with FY2025 R&D expenses of €177.8 million and net loss of €336.1 million. The cash position of €530.4 million at year-end 2025 has been augmented by a $920 million public offering in July 2026, extending runway into Q2 2029. The company is investing heavily in US commercialization infrastructure, including a Waltham, Massachusetts headquarters and a senior leadership team recruited from Takeda (Entyvio), AstraZeneca-target CinCor, Landos Biopharma, and Roche/Genentech, with a first US launch targeted for 2027. Beyond obefazimod, Abivax holds a proprietary chemical library supporting follow-on compound research in inflammation.

Abivax firmographics

Firmographics
Name
Abivax
Legal name
Abivax SA
Website
https://abivax.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Abivax is a clinical-stage biotechnology company developing obefazimod, a first-in-class oral miR-124 enhancer, for ulcerative colitis and Crohn's disease, with NDA submission planned for Q4 2026.
Ownership category
akta.pro rank

Where Abivax is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Abivax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. No Current Revenue: Abivax is a clinical-stage biotechnology company with no approved products or commercial revenue. The company reported a net loss of €48.5 million in Q1 2026 and a full-year 2025 net loss of €336.1 million. R&D expenses were €49.5 million in Q1 2026 and €177.8 million for full-year 2025.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Abivax product offering

Product offering

Core offering

Abivax is developing obefazimod (ABX464), an investigational oral once-daily small molecule and the first clinical-stage enhancer of microRNA-124 (miR-124) expression in immune cells, designed to stabilize the dysregulated inflammatory response in chronic inflammatory diseases. The lead indication is moderately-to-severely active ulcerative colitis (Phase 3 ABTECT program) with Phase 2b development in Crohn's disease (ENHANCE-CD), supported by a proprietary chemical library of follow-on candidates.

Product overview

Abivax is a clinical-stage biotechnology company developing obefazimod, an oral small molecule therapeutic that enhances microRNA-124 (miR-124) expression to stabilize the immune response. The company's lead product candidate, obefazimod (ABX464), is in Phase 3 development for ulcerative colitis and Phase 2b for Crohn's disease. Abivax is also evaluating obefazimod in combination therapy for UC and exploring other inflammatory indications through follow-on compound research based on the same mechanistic concept.

Differentiator

Problem solved

Functional benefit

Products and services

  • Obefazimod (ABX464) Obefazimod is an investigational, orally administered once-daily small molecule therapeutic and the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. It is being developed for chronic inflammatory diseases, with lead indication in moderately to severely active ulcerative colitis (Phase 3 ABTECT) and Phase 2b development in Crohn's disease (ENHANCE-CD).

Quantifiable outcome

  • Clinical remission rate of 50.8% (25mg) and 51.3% (50mg) versus 10.4% placebo at Week 44 in Phase 3 ABTECT maintenance trial
  • +5 more outcomes

Companies that use Abivax

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Abivax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Abivax partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • European Crohn's and Colitis Organization (ECCO)minorOthers · 21 February 2026Medical congress where Abivax presented 22 abstracts at ECCO 2026 Annual Congress including first evidence of anti-fibrotic activity and new clinical efficacy and safety analyses for obefazimod.
  • Dechert LLPminorImplementation/ SI/ Consulting Partner · 2 September 2022Dechert advised Abivax on a €49.2 million financing that funded Phase 3 trials of obefazimod for ulcerative colitis.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Abivax competitors and assessment

Company assessment

Direct peers

  • Pfizer: Pfizer markets Velsipity (etrasimod), an oral S1P modulator approved for ulcerative colitis, making it a directly comparable oral UC competitor launched into the same gastroenterology prescriber base.
  • Bristol Myers Squibb: BMS commercializes Zeposia (ozanimod), another oral UC therapy, positioning it as a directly comparable oral competitor with overlapping physician call points and payer access dynamics.

Broad incumbents

  • Eli Lilly: Lilly markets Omvoh (mirikizumab) for ulcerative colitis and Crohn's disease, making it a directly comparable IBD biologic competitor with established gastroenterology commercial infrastructure.
  • AbbVie: AbbVie dominates the IBD market with Skyrizi and Rinvoq, alongside its legacy Humira franchise; it is the leading incumbent that Abivax's oral obefazimod would need to compete against for share of voice and payer access.
  • Johnson & Johnson: J&J markets Stelara and Tremfya in IBD, two of the largest-selling UC and Crohn's therapies; it is a broad incumbent whose immunology franchise shapes the standard of care Abivax must displace.
  • Takeda: Takeda markets Entyvio (vedolizumab), a ~$4.7B IBD biologic, and is the company Abivax hired its incoming CCO from — a directly comparable UC franchise and benchmark for Abivax's commercial ramp.

Emerging players

  • Landos Biopharma: Landos is a smaller IBD-focused biotech (now part of AbbVie) whose leadership overlaps with Abivax's CMO, making it a thematic emerging peer in ulcerative colitis pipeline development.

Others

  • Alnylam Pharmaceuticals: Alnylam is a leader in RNA-based therapeutics and shares a mechanistic adjacency with Abivax, whose entire MOA is built around enhancing the microRNA miR-124 — making it thematically relevant as an RNA-platform comparator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Abivax social profiles

Digital presence

Abivax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abivax leadership team

Management profile

Number of profiles

Profiles17 records

Abivax funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abivax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abivax

What does Abivax do?

Abivax is developing obefazimod (ABX464), an investigational oral once-daily small molecule and the first clinical-stage enhancer of microRNA-124 (miR-124) expression in immune cells, designed to stabilize the dysregulated inflammatory response in chronic inflammatory diseases. The lead indication is moderately-to-severely active ulcerative colitis (Phase 3 ABTECT program) with Phase 2b development in Crohn's disease (ENHANCE-CD), supported by a proprietary chemical library of follow-on candidates.

Is Abivax a public or private company?

Abivax is a public company. It is classified as public and is currently operating.

When was Abivax founded?

Abivax was founded in 2013. It employs 101 to 250 people.

Where is Abivax based?

Abivax is headquartered in Paris, France, in the Europe region.

How does Abivax make money?

One revenue line is on record: no Current Revenue.

Who are Abivax's main competitors?

Direct peers on record are Pfizer and Bristol Myers Squibb. Broad incumbents are Eli Lilly, AbbVie, Johnson & Johnson and Takeda. Landos Biopharma is listed as an emerging player. Alnylam Pharmaceuticals is listed as an others.

Does Abivax have an API?

No public API is recorded for Abivax.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvfnABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 30.09.26Abivax disclosed its share capital and voting rights for 30 September 2026, with 87,541,485 shares and 88,796,742 voting rights. The company, a biotech focused on inflammatory diseases, is developing obefazimod in phase 3 for rectal bleeding.American Banking and Market NewsWedbush Issues Pessimistic Forecast for Abivax (NASDAQ:ABVX) Stock PriceWedbush cut Abivax's price target to $96 from $118, keeping a neutral rating. The stock opened at $90.23, and the company reported Q2 EPS of -$1.71, missing estimates by $0.79. Analysts forecast a -4.19 EPS for the current fiscal year.American Banking and Market NewsGuggenheim Reaffirms Buy Rating for Abivax (NASDAQ:ABVX)Guggenheim reaffirmed a buy rating on Abivax with a $175 price target, implying 93.95% upside from the previous close. The stock traded down to $90.23, and the company reported a Q2 loss of $1.71 per share, missing the consensus estimate of -$0.92.American Banking and Market NewsAbivax’s (ABVX) “Buy” Rating Reiterated at GuggenheimGuggenheim reiterated a buy rating on Abivax with a $175 price target, implying 93.95% upside from the previous close. The stock fell 3.5% to $90.23 on Tuesday, while the company reported a quarterly loss of $1.71 per share, missing estimates. Analysts average a Moderate Buy rating with a $155 target.American Banking and Market NewsAbivax’s (ABVX) “Buy” Rating Reaffirmed at GuggenheimGuggenheim reaffirmed a buy rating on Abivax with a $175 target, implying 95.28% upside from the previous close. The stock traded down to $89.62, and the company reported a Q3 loss of $1.71 per share, missing estimates. Analysts have a consensus 'Moderate Buy' rating with a $155 target.American Banking and Market NewsAbivax (NASDAQ:ABVX) Given “Buy” Rating at GuggenheimGuggenheim reiterated a Buy rating on Abivax with a $175 price target, implying 97% upside. The stock fell to $88.82, and Abivax reported Q2 EPS of -$1.71, missing estimates by -$0.79. Analysts forecast a -4.04 EPS for the current year.American Banking and Market NewsAbivax (NASDAQ:ABVX) Stock Rating Reaffirmed as “Buy” by GuggenheimGuggenheim reaffirmed its Buy rating on Abivax with a $175 price target, implying 89% upside from the previous close. The stock traded down 1% to $92.58, while analysts' consensus target is $155. The company reported a quarterly loss of $1.71 per share, missing estimates.American Banking and Market NewsAbivax (NASDAQ:ABVX) Stock Keeps Buy Rating at GuggenheimGuggenheim reaffirmed its buy rating on Abivax with a $175 price target, implying 87.19% upside from the previous close. The stock opened at $93.49, and the consensus price target is $155.00. Abivax reported a loss of $1.71 per share for the quarter, missing estimates.American Banking and Market NewsAbivax (NASDAQ:ABVX) Earns “Buy” Rating from GuggenheimGuggenheim restated a buy rating on Abivax with a $175 price target, implying 87.19% upside. The stock opened at $93.49, and the company reported Q2 EPS of -$1.71, missing the -$0.92 consensus. Analysts expect -$4.04 EPS for the current year.MarketBeatWedbush Issues Pessimistic Forecast for Abivax (NASDAQ:ABVX) Stock PriceWedbush cut its Abivax price target to $96 from $118, keeping a neutral rating. The stock opened at $92.59, and analysts have a consensus Moderate Buy with an average price target of $155. Abivax reported a loss of $1.71 per share for the quarter, missing estimates.